<i id='E3BF17C926'><strike id='E3BF17C926'><tt id='E3BF17C926'><pre id='E3BF17C926'></pre></tt></strike></i> 
EQRx is done, sold for its cash.
The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.
advertisement
The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTED Log In
Apple is now the first public company to be valued at $3 trillion 
Investment in vaccine development is lagging, report finds 
Affirmative action in medical school literally saved lives 
Venture capital firm's plans to take over Akron hospital face hurdles 
New air purifier tech could be key to improving indoor air quality 
Russian and Belarusian players banned from a women's tennis tournament in Prague
New air purifier tech could be key to improving indoor air quality 
Poland's lawmakers approve a divisive law on Russian influence 
Anesthesiologist group: stop taking Ozempic before surgery 
Typhoon Doksuri makes landfall in China after bringing deadly landslides to Philippines 
Dobbs anniversary: the lost opportunity of abortion as health care
Poland's lawmakers approve a divisive law on Russian influence 
Moonlake's readout produced a cash windfall. Risks remain 
Medicare Advantage insurers face 0.2% cut to 2025 payments 
How to save PrEP access — and even expand it 
